Printed from Voxsanity (voxsanity.com.au) — NCT06102707 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
Back to Ovarian Cancer
Ovarian Cancer Trial, Not Yet Recruiting
NCT06102707
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- People who are willing to take part voluntarily, sign a consent form, follow the study rules, and attend follow-up appointments.
- Women aged 18 or older at the time of signing the consent form.
- People who have been confirmed by pathology (laboratory testing of tissue) to have high-grade serous ovarian cancer, fallopian tube cancer, or primary peritoneal cancer, or moderately or poorly differentiated ovarian endometrioid adenocarcinoma, where the disease got worse within 6 months (182 days) of their last platinum-based chemotherapy.
- People who have received at least 3 cycles of chemotherapy.
- People whose disease has not progressed after completing chemotherapy, and who can be enrolled in the trial within 6 weeks of their last chemotherapy dose.
- People who are able to provide a tumour tissue sample that has been preserved using a standard method called formalin-fixation and paraffin-embedding (FFPE).
- People with an Eastern Cooperative Oncology Group (ECOG) performance score of 0 or 1, meaning they are fully active or restricted in strenuous activity but able to carry out light work (confirm with trial site).
- People whose major organ function meets specific blood and chemistry test thresholds, without having received blood products or growth factor treatments in the 14 days before joining the trial (confirm exact values with trial site).
- People who could potentially become pregnant must use at least one medically approved form of contraception during treatment and for 3 months after treatment ends, must have a negative pregnancy blood test within 72 hours before joining, and must not be breastfeeding.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People who have had another cancer in the past 5 years or currently have another cancer, unless it was skin basal cell carcinoma, cervical carcinoma in situ, or breast cancer with no recurrence for more than 3 years after completing curative surgery.
- People who have previously received both a PARP inhibitor (such as olaparib or niraparib) and a small molecule VEGF inhibitor (such as anlotinib or apatinib) — though having received only one of these types of drugs does not exclude someone.
- People who have untreated cancer that has spread to the brain or the lining of the brain, or who have previously treated brain or meningeal metastases that have not been confirmed as stable by imaging for at least 1 month, or who stopped systemic steroid treatment less than 2 weeks ago (confirm with trial site).
- People who have experienced a bowel obstruction or a hole in the gastrointestinal tract (gastrointestinal perforation) within the past 3 months.
- People who are unable to swallow tablets normally or have a digestive system problem that may affect how the body absorbs the study drug, as assessed by the research team.
- People who have cancer-related fluid build-up in the abdomen or around the lungs that is causing symptoms and requires draining, or who have had such fluid drained in the 3 months before joining.
- People with serious heart conditions that are not well controlled, such as moderate-to-severe heart failure, unstable chest pain (angina), a heart attack within the past year, significant irregular heart rhythms requiring treatment, or a prolonged QTc interval on a heart tracing (over 470ms).
- People with high blood pressure that remains uncontrolled despite taking blood pressure medication (systolic at or above 140mmHg or diastolic at or above 90mmHg).
- People who have had a significant bleeding event (rated grade 2 or above on a standard medical scale) in the 4 weeks before joining.
- People with a current or past history of certain lung conditions, including idiopathic pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation-related lung damage, drug-induced lung damage, or active pneumonia seen on a CT scan during screening.
- People with abnormal blood clotting test results, a tendency to bleed, or who are currently receiving clot-dissolving or blood-thinning treatments (note: low-dose preventive use of low-molecular-weight heparin or aspirin is allowed during the trial).
- People who have had a blood clot or stroke-related event in the 6 months before joining, such as a stroke, mini-stroke (TIA), brain bleed, brain infarction, deep vein thrombosis, or pulmonary embolism.
- People with a hereditary or acquired bleeding or clotting disorder, or who have had significant bleeding symptoms in the 3 months before joining, such as gastrointestinal bleeding or a bleeding stomach ulcer.
- People who have an active infection or have had an unexplained fever of 38.5°C or higher in the 7 days before joining.
- People with a congenital or acquired immune deficiency (such as HIV), or active hepatitis B or hepatitis C infection (as defined by specific test result thresholds — confirm with trial site).
- People who had surgery, radiation, chemotherapy, or hormone therapy less than 4 weeks before joining, or who still have side effects from previous treatment (other than hair loss) that have not recovered to a mild level.
- People who are likely to receive other cancer treatments or plan to have tumour-reduction (debulking) surgery during the study period.
- People who, in the judgement of the research team, have other factors that could make it unsafe or impractical to continue in the study, such as serious other illnesses, major abnormal test results, or significant personal or social circumstances affecting their ability to participate safely.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
Contact this trial
Phone: 0086-0531-82169035
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Status
Not Yet Recruiting
Phase
Not Applicable
Sponsor
Qilu Hospital of Shandong University
Registry
ClinicalTrials.gov
Start date
1 November 2023
Est. completion
1 November 2025
This date has passed while the registry still lists the trial as open to participants. Sponsors often update a trial's status without revising its projected end date, so it may well still be recruiting — but the record is out of date in at least one respect. Check with the study contact before relying on either.
Primary endpoints
Disease progression free survival
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.